BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7742526)

  • 1. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
    Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
    Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
    Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
    Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.
    Dermime S; Bertazzoli C; Marchesi E; Ravagnani F; Blaser K; Corneo GM; Pogliani E; Parmiani G; Gambacorti-Passerini C
    Clin Cancer Res; 1996 Mar; 2(3):593-600. PubMed ID: 9816208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.
    Gambacorti-Passerini C; Grignani F; Arienti F; Pandolfi PP; Pelicci PG; Parmiani G
    Blood; 1993 Mar; 81(5):1369-75. PubMed ID: 8095167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GM; D'Amaro J; Oudshoorn M; van Biezen JH; Hermans J; Willemze R; Niederwieser D
    Blood; 1999 Jun; 93(11):3863-5. PubMed ID: 10339494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
    Cullis JO; Barrett AJ; Goldman JM; Lechler RI
    Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
    Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
    Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; Biezen JH; Hermans J; Willemze R; Roosnek E; Niederwieser D
    Leukemia; 2000 May; 14(5):859-62. PubMed ID: 10803518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
    Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
    Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
    Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
    Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
    Norbury LC; Clark RE; Christmas SE
    Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
    Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
    J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.
    Gambacorti-Passerini C; Bertazzoli C; Dermime S; Scardino A; Schendel D; Parmiani G
    Clin Cancer Res; 1997 May; 3(5):675-83. PubMed ID: 9815736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
    Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
    Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes.
    Paietta E; Goloubeva O; Neuberg D; Bennett JM; Gallagher R; Racevskis J; Dewald G; Wiernik PH; Tallman MS;
    Cytometry B Clin Cytom; 2004 May; 59(1):1-9. PubMed ID: 15108165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
    Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.